Comments for DNA - Stockpickr! Your Source for Stock Ideas

Comments for DNA

Added By	Comments	Type	Date Added
Glenn MacNaughton	The next big thing.	Love	March 13, 2009
barrons3	Look at that money flowing out of Genentech (DNA) and into the other high-growth health care companies.	Love	March 12, 2009
barrons3	Keep an eye on Genenech (DNA), counsels Huckman. If you're willing to take a risk on data, the results on Avastin are due soon. If they're strong the stock could go to $100 and maybe even put it out of Roche’s reach in their acquisition attempt.	Love	March 04, 2009
bartsharkattack	obama plan	Hate	February 26, 2009
barrons3	Karen Finerman recommends looking at call spreads in Genentech (DNA).	Love	February 25, 2009
sarah z	From a recent Mad Money show:"No, DNA is played out. Let's catch the next one. "	Love	January 28, 2009
barrons3	Mike Huckman recommends keeping a eye on Roche (RHHBY) and Genetech (DNA).	Love	January 14, 2009
RhinoStocks	This biotech stock is moving horizontally meaning that a breakout could happen any time. Fitzpatrick recommended buying around $83 with a stop around $81 just in case the New Year’s volatility got the best of DNA.	Love	January 13, 2009
sarah z	From a recent Mad Money show:"No, that deal has already been made. I'm recommending Gilead Sciences (GILD) and will continue to pull the trigger on that one."	Love	January 05, 2009
sarah z	From a recent Mad Money show:"No, that deal has already been made. I'm recommending Gilead Sciences (GILD) and will continue to pull the trigger on that one."	Love	January 02, 2009
Trading Nymph	2:30	Love	December 30, 2008
sarah z	From a recent Mad Money show:"No, that deal has already been made. I'm recommending Gilead Sciences (GILD) and will continue to pull the trigger on that one."	Love	December 23, 2008
Ratilal Patel	takeover and growth	Love	December 16, 2008
eagles_carl	Watch: Buy Price: $84.50 CALL DEC08@$95 Buy Price: $82.50 PUT NOV08@$80	Love	November 05, 2008
barrons3	Outperform - Price: 79.12 on Oct. 15 by Rodman & Renshaw DNA reported 3Q08 EPS below our and consensus estimates due to one-time charges and employee-retention programs. Genentech reported 3Q08 non-GAAP diluted EPS of $0.81, compared to our and consensus estimates of $0.86 and $0.90, respectively. Total revenues of $3.412 billion were marginally above our estimate of $3.355 billion and the Street's $3.365 billion. The company ended the quarter with $1.1 billion of free cash flow and over $8.6 billion of total cash. DNA tightened FY08 non-GAAP fully diluted EPS guidance to $3.40-$3.45 from $3.40-$3.50. Investors still in the dark as to [suitor] Roche's next move....following the independent board's rejection of initial $89 per-share bid.... We anticipate an improved bid; however, until [it materializes], attention may drift from the fundamentals. We reiterate Market Outperform, $90 price target. Market cap: $83.5 billion.	Love	October 18, 2008
PaulTran92	a takeover target; came out with very strong medicines; rides the baby boomer trend	Love	October 14, 2008
HotCopywriter	Brown Group	Love	October 08, 2008
katie7ch	Making remarkable discoveries.	Love	August 24, 2008
jreres	Biotech with excellent drugs on the market	Love	August 19, 2008
Asolimando	Roche offer to purchase the company.	Love	August 01, 2008
Randi	Have an inside tract	Love	July 27, 2008
barrons2	Thank you, New York Times. Remember just a couple of weeks ago, when The New York Times wrote about how Genentech's (DNA) Avastin was too expensive and the stock got cracked down to $77? I know Roche did. I bet that was the last draw. The dramatic decline in the dollar plus a sentiment that has spawned a thousand articles -- that life-saving drugs cost too much -- gave the Swiss giant a chance to bolster its own anemic pipeline by buying what may be the greatest wonder drug of all time in its $43 billion bid, no doubt the beginning price for what will ultimately be a deal close to $100 a share. (I pushed DNA hard here and on "Mad Money" because I have been a huge believer in Avastin and I'm confident that people will pay anything -- or family members will pay anything -- for the hope of three or four months or more of life, or the chance of beating cancer altogether.)	Love	July 24, 2008
sarah z	“If you read The New York Times on last Sunday and you owned Genentech (DNA), all you could think of is, "How much money am I going to lose Monday?" The article, which I am sure had a thorough go-round in the short community, caused a blow that turned out to be the blow you buy -- the bounce off the canvas that made you bet with the underdog and win. Because of the rotation. Because of Barack Obama. Because there's no price that people won't pay for cancer abatement. Because the FDA is on the side -- rare but true -- of the people who want Avastin. I can't emphasize enough how important sea changes are. You have one here that is not only once blessed -- worldwide slowdown favors drug stocks, as I say every night on "Mad Money" this week -- but twice blessed: The Democrats hate Big Pharma but always favor drug company innovation, and DNA is the innovator, even though it can hardly be considered a small biotech company. How powerful is this rotation? Two real disappointers, two companies that totally screwed up with bad acquisitions -- Hologic (HOLX) and Inverness Medical Innovations (IMA) -- are at last catching bids. Amgen (AMGN), which has been a total disaster, is making a move back up. That seems for real. Even the suddenly hated Merck (MRK) is rocking, and I think people are way too negative on that one, too. In this rising tide, even the leakiest boats are lifting, and, funny thing, they will only go higher, because, at last, the struggling analysts who have hidden in this amazing bear market for everything drug finally have something to say, and if history is any judge, they will shout it daily from the rooftops.”	Love	July 13, 2008
kenwood	GOOD PROSPECT	Love	July 11, 2008
barrons2	Cramer credits much of Genentech's strength and future to its cancer-fighting drug Avastin. He called Avastin a "wonder drug," noting that while the drug doesn't cure cancer, Genentech has been able to continually find new uses for it. Avastin, he said, is now used for not only breast cancer but also for colon and lung cancer, with several other treatments in development. Cramer also likes Genentech for its myriad other drugs and its strong drug pipeline, which he feels will give the stock many catalysts over the next year.	Love	July 10, 2008
barrons2	The endless assault on the drug stocks, particularly the biotechs, seems to be running out of steam, and Celgene (CELG), Genentech (DNA) and Gilead (GILD) are attracting buyers, the latter close to its 52-week-high.	Love	July 02, 2008
barrons2	Cramer pointed out that biotech stocks like Gilead (GILD), Celgene (CELG), Amgen (AMGN), Merck (MRK) and Genentech (DNA) are all trading higher. “This makes sense when you consider the calendar in 1990 and where we are troughing,” Cramer said. “It’s most likely a bet that the economy’s really going to be soft. If it plays out the way it did in 1990, you’ve got a six-month move here,” he continued.	Love	July 02, 2008
lilili	Has some very interesting products in the pipeline. It's the leading bio-tech in its field. Will do very well.	Love	June 02, 2008
FoxJohnSix	iffy	Love	June 02, 2008
FoxJohnSix	iffy	Love	June 02, 2008